GENE ONLINE|News &
Opinion
Blog

2021-09-06| Trials & Approvals

BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer

by Rajaneesh K. Gopinath
Share To
On September 1st, BeiGene announced that the FDA has greenlit its Brukinsa (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) for treating adult patients with a rare type of lymphoma called Waldenström’s macroglobulinemia (WM).

This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.

GO Prime with only $1.49 now

LATEST
Orna Therapeutics Secures Multi-Billion RNA Deal With Merck After $221 Million Series B
2022-08-17
FDA Allows Sales of Over-the-Counter Hearing Aids After Five Years of Consideration
2022-08-17
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
GSK’s Second Billion Dollar Acquisition Outprices their First of 2022
2022-08-16
Despite Global Acceptance, The UK Refuses to Buy AstraZeneca’s Evusheld, Citing ‘Insufficient Data’
2022-08-16
Antibody Treatment for Multiple Varieties of CoronaVirus
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-14
Bio Asia Pacific 2022
Tailand
2022-09-14
The Future of Health
Online
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!